Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647005 | 0.86 | KDR (0.48) | KDM4ENPSR1KDRNPC1MAOA | |
| SCHEMBL4289768 | 0.84 | MPO (0.43) | KDRKLKB1DGAT1MPOKCNH2 | |
| SCHEMBL1646095 | 0.81 | ALDH1A1 (0.44) | KDM4ENPSR1DGAT1ALDH1A1 | |
| SCHEMBL1646424 | 0.80 | KDM4E (0.41) | KDM4ENPSR1NPC1DGAT1ALDH1A1 | |
| SCHEMBL408901 | 0.79 | NPC1 (0.60) | KDM4ENPSR1NPC1DGAT1THRB | |
| SCHEMBL4297507 | 0.79 | DGAT1 (0.76) | DGAT1 | |
| SCHEMBL24303811 | 0.78 | CA12 (0.56) | KDM4ENPSR1NPC1DGAT1ALDH1A1 | |
| SCHEMBL408365 | 0.78 | DGAT1 (0.59) | KDM4ENPSR1KDRNPC1DGAT1 | |
| SCHEMBL4403553 | 0.78 | DGAT1 (0.64) | KLKB1DGAT1 | |
| SCHEMBL408172 | 0.78 | NPSR1 (0.60) | NPSR1KDRNPC1DGAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| EP-2467378-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG Life Sciences Ltd (KR) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2044055-A2 | AMIDE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | KDM4E 2891/4885NPSR1 3199/4885KDR 4711/4885 |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | XDH, PNPO, AOX1 | KDM4E 2194/4885NPSR1 2291/4885KDR 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.